Clopidogrel in ST-elevation myocardial infarction
Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
Corresponding author. E-mail address: msabatine{at}partners.org
Platelet adhesion, activation, and aggregation are central to the pathophysiology of the acute coronary syndromes (ACS). Clopidogrel, an oral thienopyridine derivative, is a platelet adenosine diphosphate (ADP)-receptor antagonist capable of inhibiting platelet activation. The benefits of clopidogrel in patients with stable coronary artery disease undergoing elective percutaneous coronary interventions (PCI) and in patients presenting with non-ST-elevation ACS are well established. This article will review the results of recent clinical trials in which the utility of clopidogrel in patients with ST-elevation myocardial infarction was evaluated.
Key Words: Clopidogrel Fibrinolysis ST-elevation myocardial infarction